0.308

0.98% 0.003

After Hours: .30 -0.008 -2.60%

Cara Therapeutics Inc (CARA)

Overview News Price History Option Chain Financials Why CARA Down? Discussions Forecast Stock Split

Cara Therapeutics Inc stock is traded at $0.308, with a volume of 190.00K. It is up +0.98% in the last 24 hours and down -14.44% over the past month. Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Previous Close:

$0.305

Open:

$0.305

24h Volume:

190.00K

Relative Volume:

0.31

Market Cap:

$16.67M

Revenue:

$20.97M

Net Income/Loss:

$-118.51M

P/E Ratio:

-0.1495

EPS:

-2.06

Net Cash Flow:

$-94.45M

1W Performance:

+2.33%

1M Performance:

-14.44%

6M Performance:

-66.15%

1Y Performance:

-81.67%

1-Day Range:

$0.30

$0.315

1-Week Range:

$0.2721

$0.315

52-Week Range:

$0.24

$1.68

Cara Therapeutics Inc Stock (CARA) Company Profile

Name

Cara Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

203-406-3700

Address

400 ATLANTIC STREET, SUITE 500, STAMFORD, CT

Employee

Twitter

Next Earnings Date

2024-08-05

Latest SEC Filings

CARA's Discussions on Twitter

Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-08-23	Downgrade	BofA Securities	Neutral → Underperform
Mar-08-22	Upgrade	JP Morgan	Neutral → Overweight
Nov-01-21	Resumed	Canaccord Genuity	Buy
Aug-03-21	Initiated	JP Morgan	Neutral
Apr-21-20	Reiterated	H.C. Wainwright	Buy
Aug-12-19	Reiterated	H.C. Wainwright	Buy
May-29-19	Reiterated	Laidlaw	Buy
Feb-06-19	Resumed	Jefferies	Buy
Jan-15-19	Initiated	BofA/Merrill	Neutral
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-13-18	Initiated	Jefferies	Buy
Aug-08-18	Reiterated	Stifel	Buy
Jun-28-18	Reiterated	H.C. Wainwright	Buy
Mar-12-18	Resumed	H.C. Wainwright	Buy
Feb-12-18	Upgrade	Janney	Neutral → Buy
Jan-19-18	Initiated	Seaport Global Securities	Buy
Jun-30-17	Downgrade	Janney	Buy → Neutral
Jun-30-17	Reiterated	Laidlaw	Buy
Jun-30-17	Reiterated	Stifel	Buy
Mar-28-17	Reiterated	H.C. Wainwright	Buy
Mar-28-17	Reiterated	Laidlaw	Buy
Mar-10-17	Reiterated	Laidlaw	Buy
Oct-13-16	Initiated	H.C. Wainwright	Buy
Aug-08-16	Reiterated	Needham	Buy

View All

Cara Therapeutics Inc Stock (CARA) Latest News

09:10 AM

Market Recap: Cara Therapeutics Inc (CARA)’s Positive Momentum, Closing at 0.31 - The Dwinnex

09:10 AM

Sep 26, 2024

Stock Analysts’ New Coverage for September 26th (AINC, AIRI, APTO, BLK, CARA, CBOE, CLLS, CME, CMLS, CTLT) - Defense World

Sep 26, 2024

Cara Therapeutics (NASDAQ:CARA) Receives New Coverage from Analysts at StockNews.com - Defense World

Sep 26, 2024

Sep 25, 2024

Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com Canada

Sep 18, 2024

Aclaris Therapeutics neutral rating reiterated on phase 2a trial - Investing.com

Sep 18, 2024

Federated Hermes Inc. Acquires Shares of 670,468 Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Sep 18, 2024

Carmat launches capital increase, stock plummets - Marketscreener.com

Sep 18, 2024

Sep 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSAGE - PR Newswire

Sep 17, 2024

What technical indicators reveal about CARA stock - US Post News

Sep 17, 2024

Sep 16, 2024

The time has not yet come to remove your chips from the table: Cara Therapeutics Inc (CARA) - SETE News

Sep 16, 2024